Article Text

Download PDFPDF

E-116 Long-term mortality after carotid stenting
  1. L Rinaldo1,
  2. A Bhargav2,
  3. C Arnold Fiebelkorn3,
  4. G Lanzino1
  1. 1Neurosurgery, Mayo Clinic, Rochester, MN
  2. 2Mayo Clinic Alix School of Medicine, Mayo Clinic, Rochester, MN
  3. 3Neurology, Mayo Clinic, Rochester, MN


Background Carotid artery stenting (CAS) is an established procedure for the treatment of atherosclerotic disease affecting the extracranial internal carotid artery. Recent population-based studies have suggested that long-term survival after CAS may be limited, thereby questioning its efficacy in a real-world scenario.

Methods We retrospectively reviewed outcomes of patients undergoing CAS for asymptomatic or symptomatic carotid stenosis by a neurosurgeon or interventional neuroradiologist at our institution between 2008 and 2018. Patient and disease characteristics were recorded, as was the incidence of peri-procedural and overall ischemia and mortality after CAS. Risk factors for recurrent ischemia and mortality were identified using a Cox proportional hazards model.

Results There were 238 patients who met inclusion criteria. Mean age was 69.7 years and the majority of patients were male (69.7%). Most patients had one or two major comorbidities (52.9%), and 21.4% had more than two major comorbidities. 62.2% underwent CAS for symptomatic carotid stenosis. Fourteen patients (5.9%) experienced new or recurrent ipsilateral ischemia during follow-up, with eight (3.4%) experiencing a stroke with permanent neurologic deficit. 59 patients (24.8%) died during follow-up with a median to time to death of 111.3 months (95% CI: 95.1 – 133.6) on Kaplan-Meier analysis. Increasing age at time of CAS (Unit Risk ratio (1.06, 95% CI 1.02–1.10, p=0.005) and more than two major comorbidities (RR 3.82, 95% CI 1.28–11.49, p=0.02) were independent risk factors for mortality during follow-up.

Conclusion Unlike population-based studies, our results indicate acceptable long-term survival rates after CAS in adequately selected patients.

Disclosures L. Rinaldo: None. A. Bhargav: None. C. Arnold Fiebelkorn: None. G. Lanzino: None.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.